Incretin and metabolic peptides studied for glycemic control and fat loss.
Metabolic peptides are among the most clinically validated classes in modern medicine. The incretin axis — GLP-1, GIP, and glucagon receptor signaling — coordinates insulin secretion, satiety, gastric emptying, and energy expenditure, and engineered agonists of these receptors now anchor the treatment of type 2 diabetes and obesity.
Research in this area spans single-, dual-, and triple-receptor agonists, amylin analogs, and adipose-selective fragments. Endpoints commonly studied include glycemic control, body-weight reduction, MASH/hepatic-fat resolution, and cardiovascular risk — with half-life extension (fatty-acid acylation, DPP-4 resistance) a recurring engineering theme.
Long-acting GLP-1 receptor agonist for glycemic control and weight management.
View profileDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
View profileInvestigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.
View profileLong-acting amylin analog studied alongside semaglutide as CagriSema.
View profileGHRH analog FDA-approved for HIV-associated lipodystrophy.
View profileMitochondrially-encoded peptide with reported insulin-sensitizing activity.
View profileC-terminal hGH fragment (177–191) historically investigated for lipolysis.
View profileSmall-molecule NNMT inhibitor (often catalogued alongside peptides).
View profile